GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Diabeteszentrum Bad Lauterberg im Harz
• Treatments: Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Vildagliptin

Criteria

Inclusion Criteria:

• Treatment with either diet/exercise or metformin

• HbA1c 6.5 - 9.0 %

• Fasting plasma glucose 6.0 - 11.0 mmol/l

• Body-mass-index 20.0 - 35.0 kg/m²

• Healthy controls were required to have a normal oral glucose tolerance test (75g) and no first-degree relatives with type 2 diabetes nor a personal history of gestational diabetes

Exclusion Criteria:

• Significant heart, kidney (serum creatinine ≤ 123 µmol/l in woman and ≤ 132 µmol/l in men), liver (transaminases < 2fold upper limit of normal) and gastrointestinal disease